Healthcare
Live Price
Offline$12.05
+0.00% today
1Y Change
+138.14%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 253 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RemeGen Co., Ltd. (REGMF) is a Healthcare stock with a market cap of $71.56B and listed on OTC. The stock last traded around $12.05 and up 138.1% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +85.2%, EPS growth of +146.2%, a dividend yield of 0.0%. What stands out right now is revenue +85.2%, EPS +146.2%, free cash flow +90.3% with operating margin 28.0% and ROIC 15.5%. Valuation already assumes a fairly strong business story at P/E 56.0 and price/sales 21.2. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines REGMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REGMF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
REGMF Max Drawdown
-18.11%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for REGMF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.4B
+85.5% YoY
FY Net Income
$276.3M
+127.7% YoY
Free Cash Flow
-$353.7M
+82.5% YoY
Revenue Growth
+85.2%
EPS Growth
+146.2%
Gross Margin
99.1%
Net Margin
38.2%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 1.7B | 1.1B | 768M | 1.4B |
| Gross Profit | 2.6B | 1.4B | 823M | 498M | 1.4B |
| Operating Income | 127M | -1.4B | -1.5B | -1.1B | 163M |
| EBITDA | 439M | -1.1B | -1.2B | -806M | 402M |
| Net Income | 690M | -1.5B | -1.5B | -999M | 276M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.2B | 760M | 709M | 2.1B | 1.8B |
| Total Assets | 7.3B | 5.5B | 5.5B | 6.0B | 4.2B |
| Total Liabilities | 3.6B | 3.5B | 2.1B | 1.0B | 713M |
| Shareholder Equity | 3.6B | 2.0B | 3.4B | 5.0B | 3.4B |
| Total Debt | 2.2B | 2.7B | 1.3B | 165M | 103M |
| Net Debt | 1.0B | 1.9B | 533M | -1.9B | -1.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
264M
+120.9% YoY
Capital Expenditures
617M
+18.5% YoY
Free Cash Flow
354M
+82.5% YoY
Key ratios
Gross Margin
99.1%
Operating Margin
28.0%
Net Margin
38.2%
ROE
42.3%
Debt / Equity
0.53x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.